Clinical presentation and outcome of COVID-19 infection in Type 2 Diabetes Mellitus: a preliminary data from a tertiary hospital in Jakarta during the early days of the pandemic

Kshanti, Ida Ayu; Aji, Giri; Epriliawati, Marina; Mokoagow, Muhammad Ikhsan; Nasarudin, Jerry; Magfira, Nadya; Sari, Anggraini Permata; Manurung, Annela; Djojo, Aryan Yohanes; Wardoyo, Elizabeth Yasmine; Iskandar, Martha; Darnindro, Nikko; Mardiyah, Radhiyatam

doi:10.15562/bmj.v9i3.1969

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the preliminary data obtained from Fatmawati Central General Hospital, Jakarta, Indonesia, it was found that 16 patients who were diagnosed with COVID-19 also had T2DM. Furthermore, the data reported that 68.8% of these patients were deceased (Kshanti et al 2020, Harbuwono et al 2022. COVID-19 patients with T2DM reportedly accounted for 36.4% of the positive cases in Jakarta, according to the data on 738 cases.…”

Section: Introductionmentioning

confidence: 97%

Metformin Effectiveness in Reducing Mortality among Covid-19 Patients with Type 2 Diabetes Mellitus at a Tertiary Hospital in Indonesia

Yudivaniel Zihono,

Hany Yusmaini,

Uswatun Hasanah

et al. 2023

FMI

View full text Add to dashboard Cite

Highlights: 1. As there is a scarcity of publications on the use of metformin for COVID-19 in Indonesia, the findings of this present study may contribute more insight to the existing body of research and provide data specific to the Southeast Asian population.2. This study revealed a decreased mortality rate associated with metformin use in diabetic patients with mild to moderate COVID-19 infection.3. This study suggests that diabetic patients may continue metformin treatment during a COVID-19 infection as the medication has sustained therapeutic effects. Abstract COVID-19 patients with comorbidities, such as type 2 diabetes (T2DM), have a higher mortality rate compared to those without any comorbidities. T2DM patients usually receive metformin as their first-line treatment. However, the effectiveness of metformin in reducing mortality rates still requires further analysis. The objective of this study was to analyze the effectiveness of metformin in reducing mortality rates among COVID-19 patients with T2DM. An analytic observational design with a retrospective cohort approach was used in this study. Samples were acquired from hospitalized COVID-19 patients with T2DM medical records at Fatmawati Central General Hospital, Jakarta, Indonesia, throughout 2020–2021. The samples were collected using a purposive sampling technique and analyzed using Chi-square test (p<0.05; RR<1). This study comprised 137 samples, with 56 samples receiving metformin and 81 not receiving metformin. The mortality rate in the sample group that received metformin was lower (19.6%) compared to the group that was not given the medication (38.3%). The Chi-square test results indicated a statistically significant relationship between metformin treatment and a lower mortality rate among COVID-19-contracted individuals with T2DM (p=0.020; RR=0.513). Therefore, this study concludes that the administration of metformin treatment reduces mortality among COVID-19 patients with T2DM.

show abstract

Section: Introductionmentioning

confidence: 97%

Metformin Effectiveness in Reducing Mortality among Covid-19 Patients with Type 2 Diabetes Mellitus at a Tertiary Hospital in Indonesia

Yudivaniel Zihono,

Hany Yusmaini,

Uswatun Hasanah

et al. 2023

FMI

View full text Add to dashboard Cite

show abstract

“… 3 , 4 Our preliminary data in early pandemic documented half of individuals with diabetes admitted to our hospital due to COVID‐19 were in critical diseases with a mortality rate of over 60% in this group. 5 Identifying individuals with diabetes who are at higher risk of having clinical deterioration is of clinical importance.…”

Section: Introductionmentioning

confidence: 99%

Increased risk of poor clinical outcome in COVID‐19 patients with diabetes mellitus and in‐hospital mortality predictors: A retrospective cohort from a tertiary hospital in Indonesia

Mokoagow,

Harbuwono,

Kshanti

et al. 2023

Endocrino Diabet & Metabol

Self Cite

View full text Add to dashboard Cite

AimTo determine association between diabetes in confirmed cases of COVID‐19 and intensive care admission and in‐hospital mortality, evaluate several laboratory parameters as mortality predictor and develop predictors of in‐hospital mortality among diabetics with COVID‐19.MethodsThis retrospective cohort recruited all cases of COVID‐19 hospitalized in Fatmawati General Hospital from March to October 2020. Inclusion criterion was RT‐PCR confirmed cases of COVID‐19 who aged 18 years and older while exclusion criteria were incomplete medical record or cannot be found and pregnant women.ResultsWe enrolled 506 participants to this study with median age of 51 years (IQR:22), female (56.32%), and diabetes (28.46%). Diabetes increased intensive care admission (adjusted OR: 2.57; 95% CI: 3.52–10.43) and in‐hospital mortality (adjusted OR: 2.50; 95% CI: 1.61–3.89). In predicting in‐hospital mortality, ferritin and lactate dehydrogenase offered an acceptable discrimination, AUC: 0.71 (95% CI: 0.62–0.79) and AUC: 0.70 (95% CI: 0.61–0.78), respectively. The optimal cut‐off of predicting mortality for ferritin was 786 g/mL and for LDH was 514.94 u/L. Factors include age above 70 years old, RBGs level on admission above 250 mg/dL or below 140 mg/dL, ferritin level above 786 ng/mL and presence of ARDS increased the odds of mortality among individuals with diabetes.ConclusionsDiabetes increases risk intensive care admission and in hospital mortality in COVID‐19. Multivariate analysis showed that older age, RBG on admission, high ferritin level, presence of ARDS increased the odds of mortality among individuals with diabetes.

show abstract

Increased Risk of Poor Clinical Outcome in COVID-19 Patients with Diabetes Mellitus and in-hospital Mortality Predictors: A Retrospective Cohort from a Tertiary Hospital in Indonesia

Mokoagow

Harbuwono

Kshanti

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Aim: To determine association between diabetes in confirmed cases of COVID-19 and intensive care admission and in-hospital mortality, evaluate several laboratory parameters as mortality predictor, and develop predictors of in-hospital mortality among diabetics with COVID-19. Methods: This retrospective cohort recruited all cases of COVID-19 hospitalized in Fatmawati General Hospital during March to October 2020. Inclusion criteria was RT-PCR confirmed cases of COVID-19 who aged 18 years and older while exclusion criteria were incomplete medical record or cannot be found and pregnant women. Results: We enrolled 506 participants to this study with median age of 51 years (IQR:22), female (56.32%), and diabetes (28.46%). Diabetes increased intensive care admission (adjusted OR:6.07;95%CI:3.52-10,43) and in-hospital mortality (adjusted OR:50;95%CI:1.61-3.89). In predicting in-hospital mortality, ferritin and lactate dehydrogenase offered an acceptable discrimination, AUC:0.71 (95%CI: 0.62-0.79) and AUC:0.70 (95%CI: 0.61-0.78), respectively. The optimal cut-off of predicting mortality for ferritin was 786 g/mL and for LDH was 514.94 u/L. Factors include age above 70 years old, RBGs level on admission above 250 mg/dL or below 140 mg/dL, ferritin level above 786 ng/mL, and presence of ARDS increased the odds of mortality among individuals with diabetes. Conclusions: Diabetes increases risk intensive care admission and in hospital mortality in COVID-19. Multivariate analysis showed that older age, RBG on admission, high ferritin level, presence of ARDS increased the odds of mortality among individuals with diabetes.

show abstract

Clinical presentation and outcome of COVID-19 infection in Type 2 Diabetes Mellitus: a preliminary data from a tertiary hospital in Jakarta during the early days of the pandemic

Cited by 3 publications

References 19 publications

Metformin Effectiveness in Reducing Mortality among Covid-19 Patients with Type 2 Diabetes Mellitus at a Tertiary Hospital in Indonesia

Metformin Effectiveness in Reducing Mortality among Covid-19 Patients with Type 2 Diabetes Mellitus at a Tertiary Hospital in Indonesia

Increased risk of poor clinical outcome in COVID‐19 patients with diabetes mellitus and in‐hospital mortality predictors: A retrospective cohort from a tertiary hospital in Indonesia

Increased Risk of Poor Clinical Outcome in COVID-19 Patients with Diabetes Mellitus and in-hospital Mortality Predictors: A Retrospective Cohort from a Tertiary Hospital in Indonesia

Contact Info

Product

Resources

About